Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. following a significant drop in stock price after the FDA issued a Complete Response Letter regarding its Biologics License Application for RP1 [2][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Replimune between November 22, 2024, and July 21, 2025, to discuss their legal rights [1][2]. - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [6]. Group 2: Allegations Against Replimune - The complaint alleges that Replimune and its executives violated federal securities laws by making false or misleading statements regarding the IGNYTE trial's prospects [4]. - It is claimed that the defendants overstated the trial's prospects, leading to the FDA deeming it inadequate, which resulted in misleading statements about the company's business and operations [4]. Group 3: Stock Market Impact - Following the FDA's Complete Response Letter on July 22, 2025, Replimune's stock plummeted over 73% during intraday trading [5].